Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 1, 2015, Pages 45-54

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Iodine refractory; Sorafenib; Sunitinib; Systemic therapy; Thyroid carcinoma; VEGF

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; CABOZANTINIB; DOXORUBICIN; LENALIDOMIDE; LENVATINIB; MOTESANIB; NINTEDANIB; PAZOPANIB; PLACEBO; RETINOIC ACID; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; IODINE; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTHRALGIA; ASTHENIA; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARCINOGENESIS; CARDIOTOXICITY; CONFUSION; DECREASED APPETITE; DESQUAMATION; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DUODENUM BLEEDING; DYSPNEA; FATIGUE; FOOT PAIN; HAND FOOT SYNDROME; HAND PAIN; HEART INFARCTION; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPOCALCEMIA; LEUKOPENIA; LIMB PAIN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROIDECTOMY; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VASCULARIZATION; WEIGHT REDUCTION; ANIMAL; CANCER GRADING; CARCINOMA; CELL TRANSFORMATION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; PROGNOSIS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84925965379     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.11.009     Document Type: Review

References (63)

1. Howlader N., Noone A.M., Krapcho M., Neyman N., Aminou R., Waldron W., et al. SEER cancer statistics review, 1975-2008 2011, 19. National Cancer Institute, Bethesda, MD.
2. Chen A.Y., Jemal A., Ward E.M. Increasing incidence of differentiated thyroid cancer in the United States 1988-2005. Cancer 2009, 115(16):3801-3807.
3. Aschebrook-Kilfoy B., Ward M.H., Sabra M.M., Devesa S.S. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011, 21(2):125-134.
4. DeLellis. Pathology and genetics of tumours of endocrine organs, 2004 [IARC Press].
5. Gild M.L., Bullock M., Robinson B.G., Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011, 7(10):617-624.
6. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19(11):1167-1214.
7. Pacini F., Castagna M.G., Brilli L., Pentheroudakis G. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v214-v219.
8. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154(6):787-803.
9. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013, 13(3):184-199.
10. Antonelli A., Fallahi P., Ferrari S.M., Mancusi C., Colaci M., Santarpia L., et al. RET TKI: potential role in thyroid cancers. Curr Oncol Rep 2012, 14(2):97-104.
11. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer; preclinical and clinical aspects. Crit Rev Oncol/Hematol 2015, 93(1):18-27.
12. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angio-genesis. J Clin Oncol 2005, 23:1011-1027.
13. Wang M.J., Crisostomo P.R., Herring C., Meldrum K.K., Meldrum D.R. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am J Physiol Reg I 2006, 291:R880-R884. 51.
14. Mor F., Quintana F.J., Cohen I.R. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004, 172:4618-4623.
15. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010, 10:505-514.
16. Lichtenberger B.M., Tan P.K., Niederleithner H., Ferrara N., Petzelbauer P., Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010, 140(2):268-279.
17. Durante C., Tallini G., Puxeddu E., Sponziello M., Moretti S., Ligorio C., et al. BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur J Endocrinol 2011, 165(3):455-463.
18. Alevizakos M., Kaltsas S., Syrigos K.N. The VEGF pathway in lung cancer. Cancer Chemother Pharmacol 2013, 72:1169-1181.
19. Kamat A., Rajoria S., George A., Suriano R., Shanmugam A., Megwalu U., et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Arch Otolaryngol-Head Neck Surg 2011, 137(11):1146-1153.
20. de Araujo-Filho V.J.F., Alves V.A.F., de Castro I.V., Lourenço S.V., Cernea C.R., Brandão L.G., et al. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid 2009, 19(11):1233-1237.
21. Luo H., Li J., Yang T., Wang J. Expression and significance of VEGF-C and VEGF-D in differentiated thyroid carcinoma. Lin chuang er bi yan hou tou jing wai ke za zhi (J Clin Otorhinolaryngol, Head Neck Surg) 2009, 23(12):531-534.
22. Yester J.W., Tizazu E., Harikumar K.B., Kordula T. Extracellular and intracellular sphingosine-1-phosphate in cancer. Cancer Metastasis Rev 2011, 30(3-4):577-597.
23. Garcia E.A., Simões K., Wakamatsu A., Ressio R.A., Alves V.A.F., Longatto-Filho A., et al. Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions. Endocr Pathol 2010, 21(2):101-107.
24. Zhou Z.H., Cui X.N., Xing H.G., Yan R.H., Yao D.K., Wang L.X. Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer. Med Princ Pract 2012, 22(1):24-28.
25. Karaca Z., Tanriverdi F., Unluhizarci K., Ozturk F., Gokahmetoglu S., Elbuken G., et al. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 2011, 164(2):277-284.
26. Klubo-Gwiezdzinska J., Junik R., Kopczynska E., Juraniec O., Kardymowicz H. The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter. Eur J Endocrinol 2007, 157(4):521-527.
27. Salajegheh A., Pakneshan S., Rahman A., Dolan-Evans E., Zhang S., Kwong E., et al. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma. Hum Pathol 2013, 44(10):2204-2212.
28. Lee S.H., Lee S.J., Jin S.M., Lee N.H., Kim D.H., Chae S.W., et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clini Exp Otorhinolaryngol 2012, 5(3):150-155.
29. Miao A., Wan M., Cheng L. Expression of COX-2 and VEGF-C in papillary thyroid carcinoma and their relationship to cervical lymph metastases. Lin chuang er bi yan hou tou jing wai ke za zhi (J Clin Otorhinolaryngol, Head Neck Surg) 2009, 23(19):881-883.
30. Nersita R., Matrone A., Klain M., Scavuzzo F., Vitolo G., Abbondanza C., et al. Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma. Clin Endocrinol 2012, 76(1):142-146.
31. Wang T., Jiang C.X., Li Y., Liu X. Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid. Zhonghua bing li xue za zhi (Chin J Pathol) 2009, 38(12):824-828.
32. Dong W., Li X., Lu X., Di B., Ma J., Cui L. Expression of Survivin and its correlation with tumor angiogenesis in differentiated thyroid carcinomas. Lin chuang er bi yan hou ke za zhi (J Clin Otorhinolaryngol) 2006, 20(21):967-969.
33. Koo B.S., Kim J.M., Seo S.T., Yoon Y.H., Kwon K.R., Kim S.H., et al. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol 2014, 21(7):2310-2317.
34. Yasuoka H., Kodama R., Hirokawa M., Takamura Y., Miyauchi A., Inagaki M., et al. Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype. J Clin Endocrinol Metab 2011, 96(11):E1857-E1861.
35. Hsueh C., Lin J.D., Wu I., Chao T.C., Yu J.S., Liou M.J., et al. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol 2011, 103(5):395-399.
36. Bass M.B., Sherman S.I., Schlumberger M.J., Davis M.T., Kivman L., Khoo H.M., et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010, 95(11):5018-5027.
37. Giatromanolaki A., Lyberakidis G., Lyratzopoulos N., Koukourakis M.I., Sivridis E., Manolas C. Angiogenesis and angiogenic factor expression in thyroid cancer. J BUON (Off J Balk Union Oncol) 2009, 15(2):357-361.
38. Grosse J., Warnke E., Wehland M., Pietsch J., Pohl F., Wise P., et al. Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells. Apoptosis 2013, 1-11.
39. Piscazzi A., Costantino E., Maddalena F., Natalicchio M.I., Gerardi A.M.T., Antonetti R., et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab 2012, 97(6):E898-E906.
40. Jeong W.J., Mo J.H., Park M.W., Choi I.J., An S.Y., Jeon E.H., et al. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol Ther 2011, 12(5):458-465.
41. Fenton M.S., Marion K.M., Salem A.K., Hogen R., Naeim F., Hershman J.M. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 2010, 20(9):965-974.
42. Gule M.K., Chen Y., Sano D., Frederick M.J., Zhou G., Zhao M., et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 2011, 17(8):2281-2291.
43. An C.M., Wang Z., Han Z.K., Li Z.J., Tang P.Z., Ma J. Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice. Zhonghua er bi yan hou tou jing wai ke za zhi (Chin J Otorhinolaryngol Head Neck Surg) 2012, 47(11):931-936.
44. D'Agostino M., Voce P., Celano M., Sponziello M., Moretti S., Maggisano V., et al. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 2012, 22(2):138-144.
45. Hoffmann S., Rockenstein A., Ramaswamy A., Celik I., Wunderlich A., Lingelbach S., et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol 2007, 264(1):74-81.
46. Verbeek H.H., Alves M.M., de Groot J.W.B., Osinga J., Plukker J.T., Links T.P., et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011, 96(6):E991-E995.
47. Schneider T.C., Abdulrahman R.M., Corssmit E.P., Morreau H., Smit J.W.A., Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radioiodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012, 167(5):643-650.
48. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26(29):4714-4719.
49. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27(10):1675-1684.
50. Brose M.S., Nutting C.M., Jarzab B., Elisei R., Siena S., Bastholt L., et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014.
51. Shen C.T., Qiu Z.L., Luo Q.Y. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer 2014, 21(2):253-261.
52. Carr L.L., Mankoff D.A., Goulart B.H., Eaton K.D., Capell P.T., Kell E.M., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16(21):5260-5268.
53. Grande Pulido E., Castelo B., Fonseca P.J., Iglesias L., Vaz M.A., Barriuso J., et al. Efficacy and tolerability of sunitinib in patients with advanced thyroid cancer out of a trial: a Spanish multicenter cohort. J Clin Oncol 2011, 29(15 (May)). (2318 Mill road, Ste 800, Alexandria, VA, 22314 USA: Amer Soc Clinical Oncology).
54. Locati L.D., Licitra L., Agate L., Ou S.H.I., Boucher A., Jarzab B., et al. Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 2014, 120(17):2694-2703.
55. Cohen E.E., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26(29):4708-4713.
56. Capdevila J., Perez J., Aller J., Manzano J., Adrian S., Zafon C., et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). J Clin Oncol (Meeting Abstracts) 2014, 32(no. 15_suppl 6027 (May)).
57. Bible K.C., Suman V.J., Molina J.R., Smallridge R.C., Maples W.J., Menefee M.E., et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11(10):962-972.
58. Leboulleux S., Bastholt L., Krause T., de la Fouchardiere C., Tennvall J., Awada A., et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012, 13(9):897-905.
59. Schlumberger M., Tahara M., Wirth L., Robinson B., Brose M., Elisei R., et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol (Meeting Abstracts) 2014, 32(no. 18_suppl LBA6008 (June)).
60. Sherman S.I., Wirth L.J., Droz J.P., Hofmann M., Bastholt L., Martins R.G., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359(1):31-42.
61. Ain K.B., Lee C., Holbrook K.M., Dziba J.M., Williams K.D. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. J Clin Oncol 2008, 26(15 (suppl)):S6027.
62. Sherman E.J., Ho A.L., Haque S., Ghossein R.A., Lisa D.M., Schoder H., et al. A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma. J Clin Oncol 2010, 28(15S):5587.
63. Bellesoeur A., Carton E., Mir O., Groussin L., Blanchet B., Billemont B., et al. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. Investig New Drugs 2014, 1-4.